According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.
Compared with the general population, patients with psoriasis face a higher risk of single- and multiple organ-based comorbidities, says a new analysis published in Anais Brasileiros de Dermatologia.
The analysis included 15 observational studies comprising 200,000 patients with psoriasis and nearly 10 million individuals from the general population. Overall, patients with psoriasis had a 20% greater risk of organ-based comorbidities (pooled relative risk [pRR], 1.20; 95% CI: 1.11-1.31). Patients with moderate or severe disease were more likely to have an increased risk of comorbidities.
“The pathogenesis of psoriasis is believed to be the result of the interaction of genetic, environmental, and immune factors,” wrote the researcher of the study. “Psoriasis has been considered to be a systemic disease that may increase risks of cardiovascular disease, metabolic syndrome, and other comorbidities. The comorbidity mechanism of psoriasis may be related to the release of pro-inflammatory molecules during chronic inflammation. More and more evidence suggest that severe or relapsing psoriasis tends to be a systemic inflammation disease.”
According to the researcher, the findings help further characterize psoriasis as a systemic inflammatory disease.
First looking at single organ-based comorbidities, the study found that compared with the general population, patients with psoriasis had increased risks of cardiovascular events, cerebrovascular disease, and liver disease:
There were no significant differences in the risks of renal and pulmonary diseases between the patients with psoriasis and the general population.
Based on previous reports indicating that patients with psoriasis experience 2 or more comorbidities, the researcher also analyzed the risk of multiple organ-based comorbidities and found that compared with the general population, there were higher risks of the following:
The researcher noted that some analyses included in the study lacked “high statistical power” due to the small number of studies included.
“The present study can provide a reference for effective clinical treatments. Lately, biological antibody therapy plays a promising role in the control of psoriatic morbidity and mortality,” wrote the author of the study, noting that the cytokines driving the pathogenesis of each organ may be the same or completely different. “If molecular mechanisms and dysregulated target cytokines in involved organs are different, then the choice of biological antibody should be totally different. No biological antibody is a panacea, and clinicians should try to provide patients with more individualized treatment plans according to organ-based comorbidities that psoriasis involved.”
According to the researcher, the pathogenesis of psoriasis and associated comorbidities may be mediated through several cytokines, including interleukin-17, IL-23, and tumor necrosis factor-ɑ.
Reference
Tang X. The risk of organ-based comorbidities in psoriasis: a systematic review and meta-analysis. An Bras Dermatol. Published online July 15, 2022. doi:10.1016/j.abd.2021.10.007
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Methotrexate May Lower Blood Pressure in Rheumatoid Arthritis
September 4th 2025Methotrexate significantly lowered systolic blood pressure compared with sulfasalazine in adults with newly diagnosed rheumatoid arthritis, suggesting potential cardiovascular benefits beyond its anti-inflammatory effects.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Prevention, Early Intervention Highlighted in Updated High Blood Pressure Guidelines
September 4th 2025A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.
Read More